AstraZeneca leans into GLP-1; Cuts looming at Bayer; Eli Lilly’s obesity approval; Endpoints Slack interview with Matt Gline; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Both Bay­er and As­traZeneca took to their Q3 up­dates to un­veil some big moves, al­beit in some­what dif­fer­ent di­rec­tions, while our team al­so high­light­ed the most in­ter­est­ing nuggets out of oth­er com­pa­nies’ earn­ings calls. Don’t miss our Slack in­ter­view with Roivant’s Matt Gline and look in­to ear­ly da­ta on in vi­vo cell ther­a­py, too.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.